| Recruiting | Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager NCT07094048 | CHU de Quebec-Universite Laval | Phase 4 |
| Recruiting | Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma NCT06348108 | Alfred Chung, MD | Phase 1 |
| Recruiting | Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myelo NCT06433947 | Opna Bio LLC | Phase 1 |
| Terminated | Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma NCT06304636 | Cartesian Therapeutics | Phase 1 |
| Recruiting | Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multip NCT05896228 | Benjamin T Diamond, MD | Phase 2 |
| Recruiting | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Can NCT06119685 | Indapta Therapeutics, INC. | Phase 1 / Phase 2 |
| Withdrawn | Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma NCT05170789 | Tulane University School of Medicine | Phase 2 |
| Completed | A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. NCT05228470 | Pfizer | Phase 2 |
| Recruiting | Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractor NCT05060627 | PETHEMA Foundation | Phase 1 / Phase 2 |
| Active Not Recruiting | Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma NCT05577000 | Thomas Martin, MD | Phase 1 |
| Withdrawn | Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma NCT04802031 | Thomas Martin, MD | Phase 2 |
| Active Not Recruiting | A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone) NCT04965155 | EMN Trial Office S.r.l. Impresa Sociale | Phase 2 |
| Completed | A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma NCT04398485 | Ionis Pharmaceuticals, Inc. | Phase 1 |
| Terminated | Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Mye NCT04649060 | Oncopeptides AB | Phase 3 |
| Completed | Retrospective Study to Describe Carfilzomib Use on Patients With Relapsed Multiple Myeloma in France in the Co NCT04811508 | Centre Hospitalier le Mans | — |
| Completed | A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed NCT04434469 | Genentech, Inc. | Phase 1 |
| Terminated | Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma NCT04119336 | Andrew Yee, MD | Phase 2 |
| Completed | First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) NCT04083534 | Regeneron Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myel NCT03158688 | Amgen | Phase 3 |
| Completed | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep NCT02722668 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Unknown | Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Follow NCT03091933 | Ciusss de L'Est de l'Île de Montréal | Phase 1 / Phase 2 |
| Completed | Non-interventional Study on Salvage Auto in Relapsed Myeloma NCT02439476 | Association for Training, Education, and Research in Hematology, Immunology, and Transplantation | — |
| Completed | ATRA, Celecoxib, and Itraconazole as Maintenance NCT02401295 | University of Iowa | Phase 1 |
| Completed | Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease NCT01949532 | Amgen | Phase 1 |
| Completed | A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide a NCT01564537 | Takeda | Phase 3 |
| Completed | Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia NCT01118689 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Completed | Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in S NCT01080391 | Amgen | Phase 3 |
| Completed | Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma NCT01272466 | Herlev Hospital | Phase 1 / Phase 2 |
| Completed | Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma NCT00603447 | Amgen | Phase 1 |
| Completed | Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma NCT00153933 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma NCT00592579 | CASI Pharmaceuticals, Inc. | Phase 2 |